RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug combo shows promise for tough head and neck cancers
Disease control CompletedThis phase 2 study tested two drugs—durvalumab and cetuximab—together in 35 people with head and neck cancer that had come back or spread and was no longer responding to standard treatments. The goal was to see if the combination could shrink tumors. The study is complete, and re…
Matched conditions: RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested a combination of two drugs, niraparib and dostarlimab, in 10 people with head and neck cancer that had come back or spread. The goal was to see if the combination could shrink tumors or slow the cancer. Participants had to be able to swallow pills and have no ot…
Matched conditions: RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug combo shows promise in head and neck cancer battle
Disease control CompletedThis study tested whether adding an experimental drug (epacadostat) to an immunotherapy (pembrolizumab) works better than standard chemotherapy for people with advanced head and neck cancer that has come back or spread. 89 adults took part. The main goal was to see how many patie…
Matched conditions: RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental combo targets HPV-Driven head and neck tumors
Disease control CompletedThis Phase 2 trial tested a combination of two immunotherapies—PDS0101 and pembrolizumab (Keytruda)—in 95 adults with HPV16-positive head and neck cancer that had returned or spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received b…
Matched conditions: RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC